449
Participants
Start Date
July 27, 2016
Primary Completion Date
March 20, 2018
Study Completion Date
June 26, 2018
Filgotinib
Tablet(s) administered orally once daily
Placebo to match filgotinib
Tablet(s) administered orally once daily
csDMARDs
csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
Huntsville
Gilbert
Covina
Hemet
La Jolla
Palm Desert
Palo Alto
Riverside
Upland
Victorville
Whittier
Aventura
DeBary
Jacksonville
Miami
Orlando
Plantation
Port Richey
Decatur
Kansas City
Wichita
Elizabethtown
Lexington
Cumberland
Frederick
Worcester
Detroit
Saint Clair Shores
Hattiesburg
Tupelo
St Louis
Lincoln
Lebanon
Freehold
Toms River
Brooklyn
Charlotte
Greenville
Salisbury
Middleburg Heights
Oklahoma City
Tulsa
Philadelphia
Wyomissing
Charleston
Columbia
Myrtle Beach
Orangeburg
Memphis
Beaumont
Corpus Christi
Mesquite
Plano
San Antonio
Webster
Buenos Aires
Caba
San Juan
Victoria Park
Ghent
Leuven
Merksem
Montpellier
Berlin
Hamburg
Ratingen
Budapest
Gyula
Székesfehérvár
Haifa
Ramat Gan
Hiroshima
Izumo
Katō
Kawagoe
Kumamoto
Narashino
Okayama
Sagamihara
Sapporo
Shinjuku-Ku
Takaoka
Takasaki
Tokorozawa
Tokyo
Tomigusuku
Chihuahua City
Distrito Federal
Mérida
Bialystok
Poznan
Warsaw
Wroclaw
Seoul
Madrid
Málaga
Sabadell
Valencia
Sankt Gallen
Doncaster
Edinburgh
Goodmayes
Harlow
Newcastle upon Tyne
Lead Sponsor
Collaborators (1)
Galapagos NV
INDUSTRY
Gilead Sciences
INDUSTRY